Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026)
Vireo Growth (VREOF) posted Depreciation & Amortization (CF) of $4.0 million for Q1 2026, down 66.43% sequentially from $11.9 million in Q4 2025, and up 566.67% YoY from $600000.0 in Q1 2025.
Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vireo Growth has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $4.0 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 566.67% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 million (up 679.43% YoY) and the FY2025 annual result came in at $16.1 million, up 535.04% from the prior year.
- Depreciation & Amortization (CF) retreated to $4.0 million in Q1 2026 per VREOF's latest filing, from $11.9 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $11.9 million in Q4 2025 and troughed at $600000.0 in Q1 2025.
- A 5-year average of $1.7 million and a median of $776991.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) declined 29.08% in 2024, then soared 1774.66% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $889195.0 in 2022, then retreated by 26.84% to $650503.0 in 2023, then dropped by 2.29% to $635583.0 in 2024, then jumped by 1774.66% to $11.9 million in 2025, then sank by 66.43% to $4.0 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4.0 million, $11.9 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 5.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 635,583.00 |
| Dec 31, 2024 | 635,583.00 |
| Sep 30, 2024 | 633,586.00 |
| Sep 30, 2024 | 633,586.00 |
| Jun 30, 2024 | 633,884.00 |
| Jun 30, 2024 | 633,884.00 |
| Mar 31, 2024 | 633,728.00 |
| Mar 31, 2024 | 633,728.00 |
| Dec 31, 2023 | 650,503.00 |
| Dec 31, 2023 | 650,503.00 |